BioCentury | Jan 22, 2021
Product Development

Jan. 22 Quick Takes: CDC updates advice on COVID vaccine dosing; plus more vaccines for COVAX and RCC approval for Opdivo-Cabometyx and more

...treat active ulcerative colitis. GSK2831781 is an anti-LAG3 cell-depleting mAb derived from the IMP731 antibody from Immutep...
...intact, is eligible for £54 million ($73 million) in remaining developmental milestones plus single-digit tiered royalties. Immutep...
...the course of the disease. TARGETSLAG3 (CD223) – Lymphocyte-activation gene 3 BC Staff BioNTech Pfizer Inc. Moderna Bristol Myers Squibb Co. Exelixis Inc. GlaxoSmithKline Immutep baseclick covid-19 cov19count cov19count...
BioCentury | Dec 12, 2020
Product Development

Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich

...which closed up $12.02 (41%) to $41.72 on Thursday, is planning a BLA submission in mid-2021. Immutep’s...
...starting monocyte count. Final overall survival data for the anti-LAG3 mAb are expected in mid-2021. Immutep...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...6544 ). And several companies will present data on therapies targeting the checkpoint protein LAG3. Immutep...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...of which remain active: BMS-986016 (ONO-4482) from Bristol-Myers Squibb Co. (NYSE:BMY), and eftilagimod alpha from Immutep...
...V-region immunoglobulin-containing suppressor of T cell activation Winnie Pong, Senior Writer, Research & Analytics Bristol-Myers Squibb Co. Immutep...
BioCentury | Jan 31, 2019
Company News

Management tracks: Calico, Apellis, Immutep

...Lackner was VP head of European commercial operations for Prothena Corp. plc (NASDAQ:PRTA). Immuno-oncology company Immutep...
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

...survival compared with no treatment. Next steps could include optimizing the vaccine to improve potency. Immutep...
BioCentury | Oct 5, 2018
Company News

Immutep, Merck KGgA, Pfizer partner for Phase I immunotherapy combo trial

...Immutep Ltd. (ASX:IMM; NASDAQ:IMMP), Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) partnered to test Immutep's eftilagimod...
...INSIGHT trial sponsored by the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH (Frankfurt, Germany). Immutep...
...Phase I TACTI-mel trial for unresectable or metastatic melanoma. Immutep presented data in June (see "Immutep...
BioCentury | Jun 29, 2018
Clinical News

Immutep reports ORR data for eftilagimod plus Keytruda in Phase I for melanoma

...30 mg subcutaneous eftilagimod every two weeks starting at the fifth Keytruda cycle. In February, Immutep...
...Ig and a dimeric protein with four extracellular domains of lymphocyte-activation gene 3 (LAG3; CD223). Immutep...
...and overall survival (OS) Status: Phase I data Milestone: NA Jaime De Leon eftilagimod alpha (IMP321, immufact imp321) Immutep...
BioCentury | Jun 9, 2018
Finance

ASCO ascent

...Inc. (NASDAQ:ZIOP) $4.27 -13% Iovance Biotherapeutics Inc. (NASDAQ:IOVA) $12.65 -13% ImmunoGen Inc. (NASDAQ:IMGN) $10.01 -13% Immutep...
BioCentury | Aug 11, 2017
Strategy

The flip-side of immunotherapy

...autoimmune diseases. In 2010, it licensed the anti- LAG3 mAb IMP731 from cancer play Immutep S.A. Immutep...
Items per page:
1 - 10 of 37
BioCentury | Jan 22, 2021
Product Development

Jan. 22 Quick Takes: CDC updates advice on COVID vaccine dosing; plus more vaccines for COVAX and RCC approval for Opdivo-Cabometyx and more

...treat active ulcerative colitis. GSK2831781 is an anti-LAG3 cell-depleting mAb derived from the IMP731 antibody from Immutep...
...intact, is eligible for £54 million ($73 million) in remaining developmental milestones plus single-digit tiered royalties. Immutep...
...the course of the disease. TARGETSLAG3 (CD223) – Lymphocyte-activation gene 3 BC Staff BioNTech Pfizer Inc. Moderna Bristol Myers Squibb Co. Exelixis Inc. GlaxoSmithKline Immutep baseclick covid-19 cov19count cov19count...
BioCentury | Dec 12, 2020
Product Development

Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich

...which closed up $12.02 (41%) to $41.72 on Thursday, is planning a BLA submission in mid-2021. Immutep’s...
...starting monocyte count. Final overall survival data for the anti-LAG3 mAb are expected in mid-2021. Immutep...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...6544 ). And several companies will present data on therapies targeting the checkpoint protein LAG3. Immutep...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...of which remain active: BMS-986016 (ONO-4482) from Bristol-Myers Squibb Co. (NYSE:BMY), and eftilagimod alpha from Immutep...
...V-region immunoglobulin-containing suppressor of T cell activation Winnie Pong, Senior Writer, Research & Analytics Bristol-Myers Squibb Co. Immutep...
BioCentury | Jan 31, 2019
Company News

Management tracks: Calico, Apellis, Immutep

...Lackner was VP head of European commercial operations for Prothena Corp. plc (NASDAQ:PRTA). Immuno-oncology company Immutep...
BioCentury | Dec 11, 2018
Distillery Therapeutics

Cancer

...survival compared with no treatment. Next steps could include optimizing the vaccine to improve potency. Immutep...
BioCentury | Oct 5, 2018
Company News

Immutep, Merck KGgA, Pfizer partner for Phase I immunotherapy combo trial

...Immutep Ltd. (ASX:IMM; NASDAQ:IMMP), Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) partnered to test Immutep's eftilagimod...
...INSIGHT trial sponsored by the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH (Frankfurt, Germany). Immutep...
...Phase I TACTI-mel trial for unresectable or metastatic melanoma. Immutep presented data in June (see "Immutep...
BioCentury | Jun 29, 2018
Clinical News

Immutep reports ORR data for eftilagimod plus Keytruda in Phase I for melanoma

...30 mg subcutaneous eftilagimod every two weeks starting at the fifth Keytruda cycle. In February, Immutep...
...Ig and a dimeric protein with four extracellular domains of lymphocyte-activation gene 3 (LAG3; CD223). Immutep...
...and overall survival (OS) Status: Phase I data Milestone: NA Jaime De Leon eftilagimod alpha (IMP321, immufact imp321) Immutep...
BioCentury | Jun 9, 2018
Finance

ASCO ascent

...Inc. (NASDAQ:ZIOP) $4.27 -13% Iovance Biotherapeutics Inc. (NASDAQ:IOVA) $12.65 -13% ImmunoGen Inc. (NASDAQ:IMGN) $10.01 -13% Immutep...
BioCentury | Aug 11, 2017
Strategy

The flip-side of immunotherapy

...autoimmune diseases. In 2010, it licensed the anti- LAG3 mAb IMP731 from cancer play Immutep S.A. Immutep...
Items per page:
1 - 10 of 37